Search This Blog

Monday, March 10, 2025

'Older American amassing credit card debt to cover expenses: AARP'

 Nearly half of Americans aged 50 and older with credit card debt are using credit cards to cover basic living expenses, with debt balances on the rise, according to a new survey by AARP.

AARP found that 47% of adults aged 50 and up who carry credit card debt are using their credit cards to pay for basic living expenses like food, housing, utilities, health care and unexpected financial needs. Among those with credit card balances, 17% used credit cards every month in the last year for those expenses.

Of the older Americans with credit card debt, 37% said they have more credit card debt than they did a year ago. Nearly half, or 48%, said they carry a month-to-month credit card balance of $5,000 or more – while 28% have a balance of at least $10,000.

"If you look at the 50 to 64 year olds, the group that is potentially on the runway ramp to retirement, this is the group that is particularly feeling the impact of credit card debt," AARP senior VP of research Indira Venkat told FOX Business in an interview. 

"What's concerning there is they have proximity and line of sight to a possible retirement," Venkat explained. "They'll have to make tough choices – choices between paying down credit card debt or saving for retirement and ensuring their retirement security. But that doesn't in any way mitigate the older adults and those who have retired, and a lot of them on fixed income, it does pose very dire challenges for them on paying off their credit card debt."

The AARP survey found that among adults over 50 with credit card debt, 26% are very worried about how long it will take to pay off their debt, with about one-in-five anticipating that it will take more than five years. 

The top drivers of credit card debt included everyday expenses like food, housing, utilities, vehicle costs and healthcare. Half of respondents in the over 50 cohort with credit card debt said healthcare expenses have contributed to their debt. Among that group, the biggest expense categories were dental expenses (46%), prescription drugs (35%) and vision care (19%).

Venkat said that there "are many older adults for whom there is no choice" when it comes to putting expenses on credit cards. "If it's a matter of putting food on the table, they really have a limited number of options for that."

Nearly half, or 46%, of respondents with adults 50 and up with credit card debt said the debt has hurt their ability to save for the future.

"That said, what I think is happening, especially for those who are on the runway to retirement, is they are making tough choices," she explained. "Do they bring down credit card debt or put away money towards retirement security? And those decisions that they are making based on the level of knowledge that they have, where there is an urgency for payment of debt, particularly in light of the higher interest card expenses they are incurring."

"At AARP, what we are doing is to make sure that they are informed, that they have access to different approaches that they can use to address credit card debt," she said of AARP's personal finance resources, which she added are accessible to the general public, including non-AARP members.

Those resources include tools like financial calculators, including one focused on paying off credit card debt, along with providing tips like what questions to ask a financial advisor, strategies for paying off debt.

"It's so much a function of who you are and your personal circumstances, but the important thing that we keep reiterating is to start now, start today. Be intentional with a plan on how you're going to bring down and address the debt. And don't get discouraged, you know, if there's a little bit of a setback, we all have that. But the more important thing is to stay on track and keep moving forward," she said.

https://www.foxbusiness.com/economy/older-american-amassing-credit-card-debt-cover-expenses-aarp-finds

Rubio Slashes 83% Of USAID Programs, Hails DOGE For Supporting "Historic Reform"

 Secretary of State Marco Rubio announced on X early Monday that, following a six-week review, the United States Agency for International Development (USAID)—a rogue agency captured by the Deep State—will see most of its programs canceled, and the State Department will oversee the remaining programs still in operation. 

"The 5200 contracts that are now cancelled spent tens of billions of dollars in ways that did not serve, (and in some cases even harmed), the core national interests of the United States," Rubio said.

He continued, "In consultation with Congress, we intend for the remaining 18% of programs we are keeping (approximately 1000) to now be administered more effectively under the State Department." 

Rubio thanked Elon Musk's Department of Government Efficiency for this "overdue and historic reform" of USAID, which had become notorious for inefficiencies and bloated bureaucracies, wasting tens of billions of dollars of taxpayer funds on programs that undermine American interests, such as funding radical, left-wing programs around the world.

This is a political catastrophe for Democrats and Rhinos. USAID was the Deep State's primary tool for advancing its far-left agenda and served as a slush fund for a vast network of NGOs—but that era is now over. 

Latest USAID reporting:

Additional color:

The move by Rubio has been well telegraphed...

Moving forward, America's interests will be put first when deciding how to allocate aid (otherwise known as statecraft) to foreign countries via the State Department. 

The era of US taxpayers funding far-left NGOs worldwide that some oppose freedom of speech, capitalism, Christianity, nuclear family, and Western values has come to an end.

https://www.zerohedge.com/political/rubio-slashes-83-usaid-programs-hails-doge-supporting-historic-reform

DOGE Says It Found $312 Million In Loans That Were Given To Kids During Pandemic

 by Jack Phillips via The Epoch Times (emphasis ours),

The Department of Government Efficiency (DOGE) said over the weekend that it found that the Small Business Administration (SBA) allegedly granted thousands of loans worth hundreds of millions of dollars to individuals who had an age listed as 11 years old or younger.

Elon Musk in the White House's Oval Office in Washington on Feb. 11, 2025. Andrew Harnik/Getty Images

In a post n social media platform X on March 8 that was reposted by Elon Musk, who leads the department, DOGE wrote that in the COVID-19 pandemic years of 2020 and 2021, the SBA granted 5,593 loans worth $312 million “to borrowers whose only listed owner was 11 years old or younger at the time of the loan.”

While it is possible to have business arrangements where this is legal, that is highly unlikely for these 5,593 loans, as they all also used an SSN with the incorrect name,” the post added, referring to a Social Security number.

It said that DOGE and the SBA are now working to investigate the matter. The Epoch Times contacted the SBA for comment Sunday.

At around the same time on Saturday, DOGE wrote in a post that it found that the SBA issued 3,095 loans for $333 million to borrowers whose age was listed at over 115 years old. Those borrowers, it said, were listed as alive in the Social Security database, and in one instance, a 157-year-old individual received loans worth $36,000, including Paycheck Protection Program and Economic Injury Disaster Loan loans.

Also Saturday, DOGE said a U.S. Department of Agriculture contract worth $10.3 million that was started for “identifying unnecessary contracts” had been canceled, noting that it was one of 162 nonessential contracts that had been terminated.

Since the start of the second Trump administration, DOGE has been combing through federal agency data to find waste that it can slash in a bid to save money. However, the organization isn’t without its critics and has faced a bevy of lawsuits, including ones questioning DOGE’s legality and the role Musk is playing.

Late on March 7, a group of labor unions asked a federal court for an emergency order to stop DOGE from accessing the Social Security data of millions of Americans.

The motion for emergency relief was was in federal court in Maryland by the legal services group Democracy Forward against the Social Security Administration and its acting commissioner, Leland Dudek. The unions want the court to block DOGE’s access to the vast troves of personal data held by the agency.

Judges have raised questions in several cases about DOGE’s sweeping cost-cutting efforts, conducted with little public information about its staffing and operations. But judges have not always agreed that the risks are imminent enough to block DOGE from government systems.

DOGE has accessed government databases, including at the Treasury and Internal Revenue Service (IRS). The Trump administration has said generally that the efforts are aimed at eliminating waste and fraud in government.

https://www.zerohedge.com/political/doge-says-it-found-312-million-loans-were-given-children-during-pandemic

Novo Nordisk A/S: CagriSema disappoints

 Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The trial included 1,206 randomised people with obesity or overweight and type 2 diabetes and a mean baseline body weight of 102 kg.

The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo.

The REDEFINE 2 trial was based on a flexible protocol, allowing patients to modify their dosing throughout the trial. After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose.

When evaluating the effects of treatment, if all people adhered to treatment1, people treated with CagriSema achieved a superior weight loss of 15.7% after 68 weeks compared to 3.1% with placebo. Weight loss of 5% or more after 68 weeks was a co-primary endpoint and was achieved by 89.7% of patients on CagriSema, compared to 30.3% by placebo.

When applying the treatment policy estimand2, people treated with CagriSema achieved a superior weight loss of 13.7% compared to 3.4% with placebo.

In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class.

https://finance.yahoo.com/news/novo-nordisk-cagrisema-demonstrates-superior-102400263.html

Lilly Among Stocks With At Least $10 M In Insider Sales Recently

 While the total value of insider sales for these stocks may be higher, we focused on sales worth $10 million or more. Out of the stocks that met this criterion, we selected the 10 stocks with insider sales ranging from $10 million to $20 million, prioritizing those with the highest insider sales within this range for further analysis.

Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points.

For each stock, we provide details on the highest individual sale, the number of insider sales exceeding $10 million year-to-date, and the company’s current market capitalization. Let’s take a look at 10 stocks with at least $10 million in insider sales since the beginning of the year.

An array of pharmaceutical pills with the company's logo on the bottle.

Eli Lilly and Company (NYSE:LLY)

Highest Individual Sale: $19,507,205.25

Number of Sales Above $10 million: 24

Market Capitalization: $835.05 billion

In the middle of this list of 10 stocks with $10 million in insider sales recently is a multinational pharmaceutical firm, Eli Lilly and Company (NYSE:LLY). Commonly known as Lilly, the Indianapolis, Indiana-headquartered company has offices in 18 countries and its products have reached approximately 125 countries worldwide. It is also one of the top 10 stocks to buy according to Lone Pine Capital.

Lilly is known for its clinical depression drugs Prozac (1986), Cymbalta (2004), and its antipsychotic medication Zyprexa (1996). Its primary revenue drivers are the diabetes drugs Humalog (1996) and Trulicity (2014).

Since the beginning of the year, one insider made 24 sales of Eli Lilly and Company (NYSE:LLY) shares. One of the transactions was worth $19.51 million, during which the insider sold 21,025 shares at a price of $927.81 per share. Currently, the stock is trading at $929.72, having gained 20.43% year-to-date.

Recently, Lilly announced it plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the U.S. This brings the company's total capital expansion commitments to more than $50 billion since 2020.

Last week, the company also confirmed that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a reversible Bruton's tyrosine kinase (BTK) inhibitor. The treatment is recommended for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have previously been treated with a BTK inhibitor. The news caused its shares to jump 2.713%, from $905.16 to $929.72 per share.

Twenty analysts have an average “Moderate Buy” rating on Eli Lilly and Company (NYSE:LLY) stock, with a price target of $1,007.50 per share, according to MarketBeat.

Overall LLY ranks 5th on our list of the stocks with at least $10 million in insider sales recently.

https://finance.yahoo.com/news/eli-lilly-company-lly-among-021842033.html

NeoGenomics Expands Oncology Testing Reach In The Northeast With Acquisition Of Pathline

 NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics’ commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence for the company in a historically under penetrated but rapidly growing geographical region of the country.

https://www.businesswire.com/news/home/20250310904423/en/NeoGenomics-Expands-Oncology-Testing-Reach-in-the-Northeast-with-Acquisition-of-Pathline

Mineralys Therapeutics' blood pressure drug meets goal in trials

 – Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at week 6 –


– Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at end of treatment, week 12 –

– Advance-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a highly statistically significant 7.9 mmHg placebo-adjusted reduction assessed by 24hr ABPM at end of treatment, week 12 –

– Lorundrostat demonstrated a favorable safety and tolerability profile in both pivotal trials –

– Full results from Advance-HTN to be presented on March 29, 2025, at the American College of Cardiology Scientific Sessions –

– Conference call today at 8:00 a.m. ET –

The Company’s management team will host a conference call today, March 10, 2025, at 8:00 a.m. ET. To access the call, please dial 1-877-704-4453 in the U.S. or 1-201-389-0920 outside the U.S. A live webcast of the conference call may be found here. A replay of the call will be available on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website (click here).